0000947871-21-000454.txt : 20210422
0000947871-21-000454.hdr.sgml : 20210422
20210422171102
ACCESSION NUMBER: 0000947871-21-000454
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210420
FILED AS OF DATE: 20210422
DATE AS OF CHANGE: 20210422
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khuong Chau Quang
CENTRAL INDEX KEY: 0001609405
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37566
FILM NUMBER: 21845598
MAIL ADDRESS:
STREET 1: C/O ORBIMED ADVISORS
STREET 2: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNLOGIC, INC.
CENTRAL INDEX KEY: 0001527599
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261824804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-401-9975
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Mirna Therapeutics, Inc.
DATE OF NAME CHANGE: 20110809
4
1
ownership.xml
X0306
4
2021-04-20
0
0001527599
SYNLOGIC, INC.
SYBX
0001609405
Khuong Chau Quang
C/O ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022-4629
1
0
0
0
Common Stock, $0.001 par value
2021-04-20
4
A
0
1666666
3.00
A
3696662
I
See Footnotes
These shares of the Issuer's common stock were sold in an underwritten public offering at a price of $3.00 per share.
These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP V") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI.
Each of the Reporting Person, GP VI, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI or OrbiMed Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
/s/ Chau Khuong
2021-04-22